NCT00128622View on ClinicalTrials.gov

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

May 31, 2009

Conditions
Breast CancerColorectal CancerLung CancerPancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

denileukin diftitox

BIOLOGICAL

recombinant fowlpox-CEA(6D)/TRICOM vaccine

BIOLOGICAL

therapeutic autologous dendritic cells

Trial Locations (2)

20007

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

27710

Duke Comprehensive Cancer Center, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

H. Kim Lyerly

OTHER

NCT00128622 - Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer | Biotech Hunter | Biotech Hunter